ENDRA Life Sciences Inc. (NDRA)
USD 3.1
(-15.76%)
USD 3.1
(-15.76%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -10.52 Million USD | 20.04% |
| 2022 | -13.15 Million USD | -14.43% |
| 2021 | -11.49 Million USD | 0.03% |
| 2020 | -11.5 Million USD | -6.07% |
| 2019 | -10.84 Million USD | -20.23% |
| 2018 | -9.01 Million USD | -94.96% |
| 2017 | -4.62 Million USD | -158.19% |
| 2016 | -1.79 Million USD | -14.23% |
| 2015 | -1.56 Million USD | -2.78% |
| 2014 | -1.52 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -2.23 Million USD | 19.77% |
| 2024 Q1 | -2.78 Million USD | -90.74% |
| 2023 FY | -10.52 Million USD | 20.04% |
| 2023 Q1 | -2.93 Million USD | 11.29% |
| 2023 Q4 | -1.45 Million USD | 53.41% |
| 2023 Q3 | -3.12 Million USD | -4.49% |
| 2023 Q2 | -2.99 Million USD | -1.88% |
| 2022 Q2 | -3.57 Million USD | -25.09% |
| 2022 Q3 | -3.41 Million USD | 4.33% |
| 2022 FY | -13.15 Million USD | -14.43% |
| 2022 Q1 | -2.85 Million USD | 7.04% |
| 2022 Q4 | -3.31 Million USD | 3.04% |
| 2021 Q2 | -3.2 Million USD | -24.24% |
| 2021 FY | -11.49 Million USD | 0.03% |
| 2021 Q1 | -2.57 Million USD | -14.26% |
| 2021 Q4 | -3.07 Million USD | -15.88% |
| 2021 Q3 | -2.65 Million USD | 17.17% |
| 2020 Q4 | -2.25 Million USD | 30.75% |
| 2020 FY | -11.5 Million USD | -6.07% |
| 2020 Q3 | -3.25 Million USD | -12.6% |
| 2020 Q2 | -2.89 Million USD | 6.76% |
| 2020 Q1 | -3.1 Million USD | 0.95% |
| 2019 Q2 | -2.32 Million USD | 15.36% |
| 2019 Q1 | -2.74 Million USD | -37.17% |
| 2019 FY | -10.84 Million USD | -20.23% |
| 2019 Q4 | -3.13 Million USD | -18.56% |
| 2019 Q3 | -2.64 Million USD | -13.56% |
| 2018 Q4 | -2 Million USD | 14.97% |
| 2018 Q3 | -2.35 Million USD | -29.21% |
| 2018 Q2 | -1.82 Million USD | 35.75% |
| 2018 Q1 | -2.83 Million USD | -23.56% |
| 2018 FY | -9.01 Million USD | -94.96% |
| 2017 FY | -4.62 Million USD | -158.19% |
| 2017 Q1 | -360.69 Thousand USD | -13.83% |
| 2017 Q4 | -2.29 Million USD | -152.11% |
| 2017 Q2 | -1.05 Million USD | -193.28% |
| 2017 Q3 | -910.93 Thousand USD | 13.89% |
| 2016 Q2 | -494.31 Thousand USD | -32.36% |
| 2016 Q4 | -316.88 Thousand USD | 47.81% |
| 2016 Q1 | -373.45 Thousand USD | 18.0% |
| 2016 Q3 | -607.11 Thousand USD | -22.82% |
| 2016 FY | -1.79 Million USD | -14.23% |
| 2015 FY | -1.56 Million USD | -2.78% |
| 2015 Q4 | -455.41 Thousand USD | 16.43% |
| 2015 Q2 | -133.23 Thousand USD | 35.97% |
| 2015 Q3 | -544.97 Thousand USD | -309.02% |
| 2015 Q1 | -208.09 Thousand USD | 0.0% |
| 2014 FY | -1.52 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Aspira Women's Health Inc. | -18.85 Million USD | 44.193% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | -31.951% |
| Intelligent Bio Solutions Inc. | -10.28 Million USD | -2.31% |
| Standard BioTools Inc. | -76.6 Million USD | 86.265% |
| Inotiv, Inc. | -81.46 Million USD | 87.085% |
| Prenetics Global Limited | -52.51 Million USD | 79.966% |
| Neuronetics, Inc. | -30.55 Million USD | 65.567% |
| Star Equity Holdings, Inc. | -4.34 Million USD | -142.079% |
| Castle Biosciences, Inc. | -67.97 Million USD | 84.523% |
| Psychemedics Corporation | -2.92 Million USD | -260.176% |
| RadNet, Inc. | 98.69 Million USD | 110.66% |
| Exact Sciences Corporation | -215.01 Million USD | 95.107% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 100.959% |
| iSpecimen Inc. | -11.16 Million USD | 5.807% |
| OpGen, Inc. | -15.68 Million USD | 32.94% |
| Exagen Inc. | -22.83 Million USD | 53.931% |
| Bionano Genomics, Inc. | -215.24 Million USD | 95.112% |
| CareDx, Inc | -101.9 Million USD | 89.675% |
| Check-Cap Ltd. | -19.28 Million USD | 45.452% |
| Twist Bioscience Corporation | -220.83 Million USD | 95.236% |
| Guardant Health, Inc. | -564.72 Million USD | 98.137% |
| Biodesix, Inc. | -41.34 Million USD | 74.552% |
| BioNexus Gene Lab Corp. | -2.59 Million USD | -305.644% |
| Precipio, Inc. | -7.62 Million USD | -38.067% |
| Natera, Inc. | -446.24 Million USD | 97.642% |
| Fulgent Genetics, Inc. | -72.69 Million USD | 85.528% |
| Sera Prognostics, Inc. | -39.82 Million USD | 73.58% |
| 23andMe Holding Co. | -321.35 Million USD | 96.726% |
| OPKO Health, Inc. | -157.02 Million USD | 93.3% |
| Personalis, Inc. | -109.93 Million USD | 90.43% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 89.194% |
| Applied DNA Sciences, Inc. | -10.95 Million USD | 3.949% |
| T2 Biosystems, Inc. | -49.66 Million USD | 78.816% |
| Neogen Corporation | 58.66 Million USD | 117.934% |
| Myriad Genetics, Inc. | -123.7 Million USD | 91.495% |
| ICON Public Limited Company | 956.15 Million USD | 101.1% |
| NeoGenomics, Inc. | -107.73 Million USD | 90.235% |
| Star Equity Holdings, Inc. | -4.34 Million USD | -142.079% |
| MDxHealth SA | -27.32 Million USD | 61.501% |
| Prenetics Global Limited | -52.51 Million USD | 79.966% |
| Illumina, Inc. | -1.06 Billion USD | 99.016% |
| DarioHealth Corp. | -56.18 Million USD | 81.276% |
| Medpace Holdings, Inc. | 336.82 Million USD | 103.124% |
| Mainz Biomed B.V. | -26.64 Million USD | 60.515% |
| Trinity Biotech plc | -27.04 Million USD | 61.099% |
| Sotera Health Company | 276.69 Million USD | 103.802% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | -31.951% |